Clinical Trial Update: New Biomarkers Evaluating Ovarian Cancer

View source ↗

Summary

A completed clinical trial (NCT01466049) sponsored by Fujirebio Diagnostics evaluating new biomarkers for ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Snippet

Sponsor: Fujirebio Diagnostics, Inc. | Conditions: Adnexal Mass | Status: COMPLETED